B7–H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors

Uday B. Maachani*,1, Umberto Tosi*,1, David J. Pisapia†, Sushmita Mukherjee‡, Christopher S. Marnell1, Julia Voronina*, Daniel Martinez§, Mariarita Santi§, Nadia Dahmane*, Zhiping Zhou*, Cynthia Hawkins# and Mark M. Souweidane*,**

*Department of Neurological Surgery, Weill Cornell Medicine, New York, NY, USA; †Department of Pathology, Weill Cornell Medicine, New York, NY, USA; ‡Department of Biochemistry, Weill Cornell Medicine, New York, NY, USA; §Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; ¶Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; #Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON Canada; **Department of Neurological Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract

B7–H3 (CD276), a member of the B7 superfamily, is an important factor in downregulating immune responses against tumors. It is also aberrantly expressed in many human malignancies. Beyond immune regulatory roles, its overexpression has been linked to invasive metastatic potential and poor prognosis in patients with cancer. Antibody-dependent cell-mediated cytotoxicity strategies targeting B7–H3 are currently in development, and early-phase clinical trials have shown encouraging preliminary results.

To understand the role of B7–H3 in pediatric central nervous system (CNS) malignancies, a comprehensive panel of primary CNS tumors of childhood was examined by immunohistochemistry for levels and extent of B7–H3 expression. In addition, B7–H3 m-RNA expression status and association with overall survival in various pediatric CNS tumor types was accessed by curating publicly available patient gene expression data sets derived from bioinformatics analysis and visualization platforms (GlioVis).

We demonstrate that B7–H3 is broadly expressed in pediatric glial and nonglial CNS tumors, and its aberrant expression, as determined by immunohistochemical staining intensity, correlates with tumor grade. Moreover, high B7–H3 m-RNA expression is significantly associated with worse survival and could potentially improve prognostication in various brain tumor types of childhood. B7–H3 can be used as a therapeutic target, given its tumor selectivity and the availability of targeted therapeutic agents to this antigen.
Introduction

B7–H3 (CD276) is a type I transmembrane protein belonging to the B7/CD28 superfamily, an important class of immune checkpoint molecules chiefly expressed on the surface of T and B cells [1,2]. In addition to immune cells, expression of B7–H3 is found in a wide variety of tissues and cell types, including nonimmune resting fibroblasts, endothelial cells, osteoblasts, and amniotic fluid stem cells and is induced on antigen-presenting cells [3–5]. The exact role of B7–H3 is controversial, and the existing literature characterizes the role of B7–H3 as either costimulatory or coinhibitory in T cell–mediated adaptive immunity [6]. Recently, numerous studies have demonstrated aberrant overexpression of B7–H3 on both tumor cells and associated stromal cells in both solid and hematologic malignancies such as melanoma, leukemia, and prostate, breast, ovarian, pancreatic, and colorectal cancers; the majority of B7–H3, however, is found in the cytoplasm rather than on the cell surface [7–15]. Normal tissues demonstrate limited expression of B7–H3; although found in many organs, the cell types expressing B7–H3 remain unclear [6].

In vitro and in vivo studies on pancreatic cancer and melanoma have found that inhibiting the expression of B7–H3 with short hairpin RNA (shRNA) decreases cell adhesion to fibronectin and reduces migration and matrigel-based invasion abilities [7,16]. Increased levels of B7–H3 in melanoma correlated with activation of JAK2/STAT3/survivin-dependent pathways, which are known to render cancer cells insensitive to chemotherapy and radiation therapy [11,15,17]. Previous studies with a limited number of patient samples have reported the presence of B7–H3 expression in central nervous system (CNS) tumors including medulloblastoma and adult glioma; the same has occurred in neuroblastoma [18–20]. Recently, efforts have focused on using B7–H3 as a prognostic and survival marker in glioblastoma (GBM) and other gliomas, across various subtypes [21]. Other studies also found it to be related to genes associated with immune response, cell proliferation, and angiogenesis [22,23]. Previously, our group demonstrated B7–H3 immunoreactivity and overexpression in diffuse midline gliomas arising in the pons — diffuse intrinsic pontine glioma (DIPG) — and its overexpression in tumor tissues compared with normal samples [12]. Such expression patterns make B7–H3 an attractive target for immunologic and cell-based therapies. For instance, we have recently demonstrated the safety and feasibility of a convection-enhanced delivery (CED) approach targeting B7–H3 with the radiolabeled monoclonal antibody 124I–8H9 in pediatric patients with DIPG [24]. In the present study, we assessed the potential clinical significance of B7–H3 expression as a therapeutic and prognostic target in a comprehensive spectrum of pediatric CNS malignancies by investigating B7–H3 immunoreactivity and RNA expression.

Materials and Methods

Patients and Specimens

Pediatric CNS tissue microarrays including astrocytomas, atypical teratoid rhabdoid tumors (ATRTs), ependymomas, CNS embryonal tumors (CETs), medulloblastomas, meningiomas, germ cell tumors, choroid plexus tumors (CPTs), and craniopharyngiomas were generated at the Department of Pathology at the Children’s Hospital of Philadelphia (CHOP) and the Department of Laboratory Medicine & Pathobiology at the Hospital for Sick Children, Toronto, ON, Canada, in accordance with and subject to the approval by the respective ethics committees and institutional review boards. Tumor phenotypes included all major categories of primary CNS tumors of childhood (Table 1). Specimens had been initially obtained either by surgical biopsy or at autopsy from patients with clinicopathologically established diagnoses. TMAs were constructed as previously described [25,26]. We note that age and sex demographics were not available for ependymoma specimens.

B7–H3 Immunohistochemistry and Image Analysis

Tumor B7–H3 expression was assessed by immunohistochemistry, with human lymph nodes serving as a positive control and rodent tissue as a negative control. Briefly, 4-μm-thick formalin-fixed sections were immunohistochemically stained for B7–H3 with antibody SP206 (1:200, OriGene Technologies) using the Leica Bond Rx automated system (Leica Biosystems, USA). The Bond Refine polymer staining kit (Leica Biosystems) was used, and antigen retrieval was performed with E2 (Leica Biosystems) retrieval solution for 20 min. Individual B7–H3 immunostained (DAB peroxidase)}
specimens on TMAs were scored microscopically by a board-certified neuropathologist (D.J.P.). Based on the histopathological assessment of the average staining intensity in at least 50% of tumor cells, tissue cores were initially scored on a 5-point scale which was then consolidated into a 3-point semiquantitative score as follows: negative (0), low (1), medium (2, 3), or high (4, 5) staining intensity.

Staining concentration was additionally quantitatively analyzed in an automated fashion using Fiji/ImageJ software (NIH, Bethesda, MD) by another investigator (S.M.). The file was grayscale (8-bit), blurred (Gaussian blur with sigma = 2), thresholded, and masked to measure the total tissue surface area. The same original images were also color-deconvoluted, and DAB-staining files were blurred (Gaussian blur with sigma = 2), thresholded, and masked to measure DAB-positive surface area. Staining concentration was defined as the ratio between DAB-positive and total tumor area in each file.

Good correlation was observed between the two quantification methods, with an increase in staining intensity (pathological score) associated with staining concentration (image analysis) (Supplementary Fig. 1).

**B7–H3 mRNA Expression Status and Survival Analysis in Patients**

We assessed B7–H3 mRNA expression status and association with overall survival in various pediatric CNS tumor types by curating publicly available patient gene expression data sets derived from the bioinformatics analysis and visualization platform GlioVis (gliovis.bioinfo.cnio.es). The patient gene expression data sets and Gene Expression Omnibus (GEO) identifiers used are as follows: pediatric medulloblastoma — Cavalli (sample size n = 763; GEO ID: gse85217) [27]; pediatric glioma — Paugh (sample size n = 53; GEO ID: gse19578) [28]; and pediatric ependymoma — Hoffman (sample size n = 65; GEO ID: gse50385) [29]. Association of B7–H3 expression to overall survival was estimated using a median or mean cutoff provided on the GlioVis platform to separate high (red) and low (blue) expressing patient groups.

**Statistical Analysis**

To investigate the associations of tumor B7–H3 expression with different clinicopathological factors, statistical analyses were conducted using one-way analysis of variance (ANOVA) and Tukey’s multiple comparison. Differences between groups were considered to be significant at a p-value of < 0.05. Statistical analyses were performed using GraphPad Prism, version 7.0 and following versions (GraphPad Software, Inc., San Diego, CA). The overall survival based on mRNA B7–H3 expression status (high or low) comparison in patients is performed using the standard univariate log-rank test, and a p-value ≤ 0.05 was considered statistically significant. Data are represented in box plots showing the minimum to maximum distribution.

**Results**

**B7–H3 Expression in Pediatric CNS Tumors**

We analyzed the expression of B7–H3 by immunohistochemistry using TMAs containing a diversity of pediatric CNS tumors. We found that expression levels were highly variable across and within tumor types, with some samples having minimal B7–H3 expression and others having an almost universal expression pattern, with staining concentrations close to 1.0 (i.e., the entire sample was positive for B7–H3). When analyzed against nontumoral brain tissue that included both the cortex and cerebellum (Figure 1A), atypical teratoid rhabdoid tumors (ATRTs) (p < 0.0001, Figure 1B), ependymomas (all grades) (p < 0.0001, see Figure 2 for grade-by-grade analysis), medulloblastomas (p < 0.0001, Figure 1C), CETs (p < 0.0001, Figure 1D), CIPTs (p = 0.003, Figure 1E), meningiomas (p < 0.0001, Figure 1F), and craniopharyngiomas (p < 0.0001, Figure 1G) all had higher B7–H3 staining concentrations than the normal brain. Analysis of B7–H3 mRNA expression within medulloblastoma subtypes was performed using publicly available data sets (Cavalli [27], on GlioVis); we observed significant differences in B7–H3 expression across histological (Supplementary Figure 2A) and molecular subtypes (Supplementary Figure 2B and 2C; all statistically significant except for the SHH-Group 3 pair). B7–H3 expression was highest in the Wnt subtype and lowest in the SHH subtype.

On the other hand, gliomas (including all grades, with a majority of low-grade samples) (p = 0.3, see Figure 2 for grade-by-grade analysis), neuronal/glial mixed tumors (p = 0.09, Figure 1H), and germ cell tumors (p = 0.9, not shown) did not differ from the normal brain in their levels of B7–H3 expression (Figure 1A).

All ATRT specimens (n = 13) (median age of 2.5 years) showed B7–H3 immunostaining, with 92.3% (n = 12) showing high and 7.6% (n = 1) medium staining intensities. All medulloblastoma samples (n = 33, median age of 6.8 years) were B7–H3 positive, with 3% (n = 1) having low, 45.4% (n = 15) medium, and 51.5% (n = 17) high staining intensities. Of the 5 CETs, 2 samples (40%) showed medium intensity and 3 (60%) showed high-intensity B7–H3 staining. Meningiomas (n = 16, median age of 17.3 years), craniopharyngiomas (n = 13, median age of 7 years), and CIPTs (n = 11, median age of 8 years) all showed some degree of labeling, with a high-intensity staining intensity of 68.7%, 76.9%, and 18.1% respectively. Neuronal and mixed neuronal-glial tumors (n = 34, median age of 11.9 years) and germ cell tumors (n = 3, median age of 18.5 years) stained positive for B7–H3 with frequencies of 17.8% (n = 5) high, 21.4% (n = 6) medium, and 60.7% low (n = 17) staining intensities (Table 1) — overall, in these cases, there was no difference in expression from the normal brain (Figure 1F).

**B7–H3 Expression Across Grade**

In trying to understand the prognostic value of B7–H3 expression, we analyzed its expression across World Health Organization (WHO) grade for those tumors where this information was available. For gliomas, we observed significantly stronger staining intensity in specimens with high-grade histopathology. 53.3% of GBMs showed high-intensity B7–H3 labeling. In DIPG, 67% demonstrated medium-intensity labeling and 14% demonstrated high-intensity labeling. In contrast, grade I pilocytic astrocytomas showed low- (48%), medium- (22%), and high (4%)-intensity B7–H3 staining of tumor specimens (Table 1). We observed that grade I (p = 0.8) and grade II (p = 0.9) gliomas did not have significantly different B7–H3 staining concentration from nontumoral brain (both the cortex and cerebellum). Grade III and IV gliomas, however, had significantly higher B7–H3 staining concentration (p < 0.0001) (Figure 2A and 2B), as did DIPG tumors (p = 0.01, Supplementary Figure 3A and 3B). The large number of low-grade samples in our cohort thus explains why the expression of B7–H3 in gliomas, as a group, is not different from that of the normal brain. Of note, the two anaplastic astrocytomas (WHO grade III) in our cohort had no B7–H3 expression. We further correlated B7–H3 mRNA expression in pediatric gliomas in publicly available datasets (Hoffman [29], on
Figure 1. B7–H3 expression in pediatric brain tumors. (A–H) Representative photomicrographs of B7–H3 immunostaining of the normal brain (A), ATRTs (B), medulloblastomas (C), CETs (D), CPTs (E), meningiomas (F), craniopharyngiomas (G), and neuronal/glial mixed tumors (H). (I) Quantification of staining concentration across various tumor types against nontumoral brain samples. ATRTs, atypical teratoid rhabdoid tumors; CETs, CNS embryonal tumors; CPTs, choroid plexus tumors.
Glioblastoma tumors which were found in both grade III (anaplastic astrocytomas and oligodendrogliomas) and IV levels of staining concentration between grade I (myxopapillary (62%, having higher concentrations than either grade I (B7
deficiency). In ependymomas, analysis revealed that all tumors demonstrated high B7
e
eH3 expression across WHO grade. (A) Representative photomicrographs of B7–H3 immunostaining across WHO grade for pediatric gliomas. (B) Quantification of staining concentration across WHO grades for pediatric gliomas (nontumoral brain, n = 11; grade I, n = 44; grade II, n = 14; grade III/IV, n = 24). (C) Kaplan-Meyer survival curves for pediatric glioma patients (Paugh data set) divided by B7–H3 mRNA expression (high being above mean and low below mean). (D) Representative photomicrographs of B7–H3 immunostaining across WHO grade for pediatric ependymomas. (E) Quantification of staining concentration across WHO grades for pediatric ependymomas (nontumoral brain, n = 11; grade I, n = 4; grade II, n = 10; grade III/IV, n = 29). (F) Kaplan-Meyer survival curves for patients with pediatric ependymoma (Hoffman data set) divided by B7–H3 mRNA expression (high being above median and low below median).

In ependymomas, analysis revealed that all tumors demonstrated labeling for B7–H3 staining with medium (38%, n = 9) or high (62%, n = 15) intensity (Table 1). Quantification showed increasing levels of staining concentration between grade I (myxopapillary ependymomas) and II tumors (p = 0.05), with grade III tumors having higher concentrations than either grade I (p < 0.0001) or grade II (p = 0.005) tumors (Figure 2D and 2E). In ependymomas, high B7–H3 mRNA expression (n = 15) was similarly associated with shorter median survival (61 months), regardless of grade, against low B7–H3 expression (n = 15; no events; p = 0.04, Figure 2F).

Each group (“high” and “low” B7–H3 expression) consisted of seven grade II tumors and eight grade III tumors, again indicating the potential role of B7–H3 expression as an adjunct predictor. When subdivided based on location, B7–H3 staining was not different between supratentorial and infratentorial and spine ependymomas (Supplementary Figure 4A, p = 0.09). When publicly available mRNA data sets were analyzed with respect to molecular subtype [29], we observed how both group A and group ST ependymomas had higher B7–H3 mRNA levels than group B ependymomas (one-way ANOVA with Tukey’s multiple comparisons, p = 0.047 and p = 0.017, respectively); there was no difference between group A and group ST tumors (p = 0.76) (Supplementary Figure 4B).

Discussion

Our group previously reported B7–H3 immunoreactivity and overexpression in DIPG and the potential for antibody-based targeted therapy against B7–H3, with a phase I clinical trial showing the safety of this approach [12,24]. However, the expression of this protein in other pediatric CNS malignancies has not been broadly investigated. To determine the potential for B7–H3 targeted agents in these malignancies, we comprehensively investigated B7–H3 protein levels in pediatric glial and nonglial CNS tumors and neuroblastomas. To our knowledge, our work provides the first large-scale evaluation of B7–H3 expression in primary CNS tumors of childhood. We show that B7–H3 protein is expressed in the vast majority of pediatric brain tumors, with high B7–H3 expression...
demonstrated in a diversity of glial and nonglial tumors and particularly in high-grade tumors; ATRT tumors, a rare entity affecting young children with particularly poor prognosis [30,31], had particularly high B7−H3 expression, with all cases (n = 13) showing at least moderate staining and 92.3% (n = 12) showing a high expression level as scored by immunohistochemistry. For medulloblastomas and ependymomas, we further show differential expression across tumor grade and molecular or histological subtype.

Our results are consistent with previous studies showing aberrant overexpression of B7−H3 in both solid and hematologic malignancies [2,3,6,8,13–15,18,20,32]. Higher B7−H3 expression in human cancer tissues of hepatic, lung, pancreatic, prostate, breast, colorectal, ovarian, and various other cancers, including adult gliomas, are reported to correlate with grade, increased recurrence, and poor prognosis [1,9,11,14,16,33].

The precise role of B7−H3 activity in cancer cells has yet to be fully elucidated [6,32]. The varied expression of B7−H3 in normal tissues may be a major mechanism of physiologic peripheral immune tolerance to dampen tissue autoimmune responses. Therefore, it is important to consider immune-related adverse events to immunotherapies when targeting this antigen. However, the almost-universal high expression in tumor tissue compared with the normal brain makes B7−H3 an inviting therapeutic target. Antibodies or antibody fragments that amplify inherent immunological properties could be exploited for the killing of B7−H3-positive cancers [32,34]. These could include complement-mediated cytosis and antibody-dependent cellular cytotoxicity (ADCC) and antibody–drug conjugate (ADC) therapies. Other more experimental approaches, such as the recruitment of cytotoxic T cells using bispecific technologies (e.g., dual-affinity retargeting [DART0 molecules or genetically reprogrammed T cells using chimeric antibody receptors [CAR-Ts]), are also in development [25,34,35]. This approach is particularly appealing for CNS malignancies, where the low B7−H3 expression observed in the normal brain parenchyma and cerebellum could potentially reduce on-target off-tumor side effects (i.e., binding to B7−H3 found outside tumor tissue). A direct drug delivery approach could further limit overall body exposure and be even more advantageous, given the variable expression of B7−H3 in different normal organs. In fact, we have already demonstrated the safety of such an approach; direct in-tumor administration of 124I−8H9, a radiolabeled monoclonal antibody against B7−H3, was recently proven safe in a phase I clinical trial in children with DIPG, with no systemic side effects directly associated with B7−H3 targeting observed [24].

In conclusion, our study demonstrates that B7−H3 protein is broadly overexpressed in pediatric glial and nonglial CNS tumors and neuroblastoma. Moreover, its expression correlates with tumor grade and prognosis in both gliomas and ependymomas. Given its tumor selectivity in the brain and the availability of targeted therapeutic agents to B7−H3, this study illustrates the potential utility of therapeutics directed to this antigen in various pediatric CNS tumors.

Conflicts of Interest
The authors have no potential conflict of interest, financial or otherwise, to disclose.

Authorship
Experimental design: UM, MMS, MS, DP, MS, CH, ND, ZZ.
Experimental implementation: UM, UT, DP, SM, DM.
Data analysis: UM, UT, CM, JV, DP, SM, DM, ZZ.
Manuscript writing and editing: UM, UT, CM, DP, SM, JV, MS, DM, ZZ, ND, CH, MMS.
Manuscript approval: all authors.

Acknowledgments
This research was supported in part by the Cristian Rivera Foundation, the Olivia Boccuzzi Foundation, the Fly a Kite Foundation, the McKenna Claire Foundation, the Lyonhearted Foundation, the Christian Koehler Foundation, the Brooke Healey Foundation, the Isabella Rose Romano Foundation, the Joshua’s Wish, the Lily LaRue Foundation, the Samuel Jeffers Childhood Cancer Foundation, the Ty Louis Campbell Foundation, and the Children’s Brain Tumor Family Foundation.

Figure 3. B7−H3 expression across nontumoral organs. (A) Representative photomicrographs of B7−H3 immunostaining of normal tissues. (B) Quantification of staining concentration in the brain cortex (n = 5), cerebellum (n = 6), lung (n = 6), muscle (n = 6), tonsil (n = 13), kidney (n = 6), liver (n = 5), GI (n = 3), placenta (n = 56), breast (n = 6), prostate (n = 6), and lymph node (n = 6).
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.tranon.2019.11.006.

References

[1] Xu H, Cheung TY, Guo HF and Cheung NK (2009). MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69, 6275–6281.

[2] Chakravai Al, Ni J, Lau JS, Wilcoxon RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G and Tamada K, et al (2001). B7-H3, a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2, 269–274.

[3] Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM and Collins M (2003). Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 82, 365–377.

[4] Picarda E, Ohaegbulam KC and Zang X (2016). Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22, 3425–3431.

[5] Sun M, Richards S, Prasad DV, Mai XM, Rudensky A and Dong C (2002). Expression of CD276/B7-H3 in human prostate cancer and associated with disease spread and poor outcome. J Invest Dermatol 133, 2050–2058.

[6] Zang X, Sullivan PS, Soslow RA, Waite R, Reuter VE, Wilton A, Thaler HT, Doherty P, Soslow RA, Waite R, Reuter VE, Wilton A, Thaler HT, et al (2009). MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69, 6275–6281.

[7] Chakravai Al, Ni J, Lau JS, Wilcoxon RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G and Tamada K, et al (2001). B7-H3, a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2, 269–274.

[8] Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM and Collins M (2003). Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 82, 365–377.

[9] Xu H, Cheung TY, Guo HF and Cheung NK (2009). MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69, 6275–6281.

[10] Chakravai Al, Ni J, Lau JS, Wilcoxon RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G and Tamada K, et al (2001). B7-H3, a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2, 269–274.

[11] Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM and Collins M (2003). Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 82, 365–377.